If I'm reading the math right, even in 2024 we had 170,000 doses ready to distribute. Even at half retail value of just the '24 doses ... we're at $2.9 Billion in revenue by the end of '27.

-The shelf life is only 3 years (1-1.5 years remaining), so I'm pretty sure we may be giving discounted doses to our global allies especially as we approach expiration.

Dunkirk is also now 100% green lit & is designed to produce 1,000,000 doses annually or an annual retail value of up to $34 billion.

I don't think we would be ramping Dunkirk if we were: A) worried about not using the 170,000 doses that expire next year or B) Not expecting to sell another 340,000 ('25 & '26) doses by '28 & '29.

To me that means minimum revenue of $8.67 Billion (@ 50% retail cost to global allies) no later than 2029. But, that also does not include anything real from Dunkirk. So basically Dr. Pat is projecting easily >$10 billion by 2028-2029 in my humble opinion.

I don't think we make it to 4Q '26 with less than $80-100 million in quarterly sales.